Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What does prostate-specific antigen recurrence mean?

C R Pound1, A W Partin

  • 1Department of Urology, The University of Tennessee College of Medicine, 1211 Union Avenue, Suite 340, Memphis, TN 38104, USA. crpound@utmem.edu

Current Urology Reports
|June 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Prostate cancer and prostatic diseases·2017
Same author

Very-high-risk localized prostate cancer: definition and outcomes.

Prostate cancer and prostatic diseases·2013
Same author

Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Radical prostatectomy in men less than 50 years old.

Urologic oncology·2011
Same author

Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.

The Journal of urology·2007
Same author

Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.

Reviews in urology·2006
Same journal

Effective Mentorship in Urology Fellowship Training: Qualities, Models, and Equity.

Current urology reports·2026
Same journal

Management of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis.

Current urology reports·2026
Same journal

Lower Urinary Tract Symptoms as an Indicator of Occult Neurologic Disease: A System-first Framework for Urologic Practice.

Current urology reports·2026
Same journal

Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis.

Current urology reports·2026
Same journal

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Current urology reports·2026
Same journal

Artificial Intelligence in Urologic Documentation: A Review of Emerging Capabilities and the Ongoing Need for Human Oversight.

Current urology reports·2026
See all related articles

Prostate-specific antigen (PSA) recurrence after prostatectomy often signals early distant disease in asymptomatic men. New methods aid decisions on treatment for recurrent prostate cancer, impacting survival.

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Prostate-specific antigen (PSA) recurrence after radical prostatectomy is the primary indicator of recurrent prostate cancer.
  • This recurrence often occurs in asymptomatic men, potentially years after surgery, raising questions about prognosis and survival.
  • Current evaluations for recurrent disease frequently lack objective clinical findings.

Purpose of the Study:

  • To clarify the implications of PSA recurrence for clinical disease progression and patient survival.
  • To inform treatment decisions for men experiencing PSA recurrence after prostatectomy.
  • To highlight recent advancements in interpreting PSA recurrence for better patient-physician decision-making.

Main Methods:

  • Review of clinical data and diagnostic evaluations for men with PSA recurrence post-prostatectomy.

Related Experiment Videos

  • Analysis of the correlation between PSA recurrence and the presence of distant versus local disease.
  • Evaluation of the impact of salvage therapies and systemic treatments on outcomes.

    • Main Results:

    • PSA recurrence is frequently an early indicator of distant metastatic disease, often present at the time of initial surgery.
    • In most cases, clinical evaluations do not reveal objective signs of disease despite detectable PSA levels.
    • The optimal timing and type of systemic therapy initiation remain subjects of clinical debate.

    Conclusions:

    • PSA recurrence signifies a high likelihood of underlying distant disease, even in asymptomatic individuals.
    • Recent advancements offer improved tools for assessing the significance of PSA recurrence.
    • Informed treatment decisions regarding systemic therapy can be made with a better understanding of PSA recurrence implications.